COVID-19 vaccine induced thyroid disease: challenges and strategies

Abstract

CLC Number:

R581

YUAN Li, XIANG Pingping, CHEN Guofang, et al . COVID-19 vaccine induced thyroid disease: challenges and strategies[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(02): 121-123.

Figures/Tables1

SARS-CoV-2抗原	SARS-CoV-2序列	映射区间	TPO序列	ID（%）
Chain A, Helicase	VLTSHT-VM	226~233	VL-SVTLVM^*	67
Chain A, Spike protein S1, S2	VLGQSKR-VD	1 020~1 028	VLEESKRLVD^*	70
Chain B, Replicase polyprotein 1a	EDKRAKVTSAM-QTM	2~5	ESKRL-VDTAMYATM^*	53
Chain A, Spike gycoprotein	NLTTRTQLPPA	48~58	NLKKRGILSPA^*	55
Chain A, nsp16	APGTAVLRQWLP	79~90	ASNTALAR-WLP^*	58
Chain A, Spike protein S1, S2	VTWFHAIHVS	49~58	VTR-HVIQVS^*	60
Chain A, Replicase polyprotein 1ab	SAARLTPCGTG	6~16	SAA-CGTG^*	64
Chain A, Replicase polyprotein 1a	LLSVLQQLR	13~21	LLRVHARLR^*	56
Chain A, Spike glycoprotein	FL-GRSLEV	1 221~1 228	FLAGDGRASEV	55
Chain A, nsp3	ADIV-EEAKKV	21~30	ADAVYQEARKV^*	64
Chain A, Main protease	LNGLWLDDTVY	27~37	LNAHWSADAVY^*	55
Chain A, Nucleoprotein	PY-G-AN	77~81	PYEGYDSTAN^*	50
Chain A, Spike glycoprotein	WVLLSTFLGRSGGGL	1 219~1 233	WTLL-R-GGGL	53
Chain A, Spike glycoprotein	VLYNSASFST	34~43	VLSNS-ST	60
Chain A, Uridylate-specific endoribonuclease	SSGVDLGTENL	8~18	SSTLDLASINL	55
Chain A, Uridylate-specific endoribonuclease	TENLYFQSNMS	15~25	TERLFVLSNSS	55
Chain A, 2’-O-methyltransferase	FV-SDADSTL	105~113	FVLSNS-STL^*	60
Chain A, Helicase	LSYGIATVREV	147~1 578	LSTAIAS-RSV^*	55
Chain A, Spike protein S1, S2	PD-VD-LG	86~91	PDNIDVWLG	56
Chain B, nsp3	RARAGEAANF-CALI	138~151	RARTG-PLFAC-LI^*	53
Chain A, Spike glycoprotein	YEQSSRENL	1 237~1 245	YELQGREQL^*	67
Chain A, Spike glycoprotein	YKLPDDFTG-CV	90~100	YELGDD-GRTCV^*	54
Chain A, 3C-like proteinase	ELLQNGMNGRT	268~278	EL-GDDGRT^*	55
S protein in complex bound with 4A8	SPRRARSVASQ	671~681	SPQRA-AAQ^*	55

References25

[1]	Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission[J]. Lancet, 2020, 395(10223): 514-523. doi:10.1016/S0140-6736(20)30154-9 URL
[2]	Ferreira LN, Pereira LN, da Fé Brás M, et al. Quality of life under the COVID-19 quarantine[J]. Qual Life Res, 2021, 30(5): 1389-1405. doi:10.1007/s11136-020-02724-xpmid:33389523
[3]	Saeed S, Awasthi AA, Nandi D, et al. Knowledge, attitude and practice towards COVID-19 among individuals with associated comorbidities[J]. J Med Life, 2021, 14(2): 225-237. doi:10.25122/jml-2020-0184pmid:34104246
[4]	Li MY, Li L, Zhang Y, et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues[J]. Infect Dis Poverty, 2020, 9(1): 45. doi:10.1186/s40249-020-00662-x
[5]	Lui DTW, Lee CH, Chow WS, et al. Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19[J]. J Clin Endocrinol Metab, 2021, 106(2): e926-e935. doi:10.1210/clinem/dgaa813pmid:33141191
[6]	Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19[J]. J Endocrinol Invest, 2020, 43(10): 1527-1528. doi:10.1007/s40618-020-01366-7pmid:32686042
[7]	Jiménez-Blanco S, Pla-Peris B, Marazuela M. COVID-19: a cause of recurrent Graves’ hyperthyroidism?[J]. J Endocrinol Invest, 2021, 44(2): 387-388. doi:10.1007/s40618-020-01440-0pmid:33025554
[8]	Montebello A. Recurrent Graves’ disease post SARS-CoV-2 infection[J]. BMJ Case Rep, 2021, 14(8): e244714. doi:10.1136/bcr-2021-244714 URL
[9]	Pastor S, Molina á Sr, De Celis E. Thyrotoxic crisis and COVID-19 infection[J]. Cureus, 2020, 12(11): e11305.
[10]	Iremli BG, Şendur SN, Ünlütürk U. Three cases of sub-acute thyroiditis following SARS-CoV-2 vaccine[J]. J Clin Endocrinol Metab, 2021, 106(9): 2600-2605. doi:10.1210/clinem/dgab373 URL
[11]	Sahin Tekin M, Şaylısoy S, Yorulmaz G. Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: a case report[J]. Hum Vaccin Immunother, 2021, 17(11): 4090-4092. doi:10.1080/21645515.2021.1947102 URL
[12]	Oğuz SH, Şendur SN, Iremli BG, et al. SARS-CoV-2 vaccine-induced thyroiditis: safety of revaccinations and clinical follow-up[J]. J Clin Endocrinol Metab, 2022, 107(5): e1823-e1834. doi:10.1210/clinem/dgac049 URL
[13]	Schimmel J, Alba EL, Chen A, et al. Letter to the editor: thyroiditis and thyrotoxicosis after the SARS-CoV-2 mRNA vaccine[J]. Thyroid, 2021, 31(9): 1440. doi:10.1089/thy.2021.0184 URL
[14]	Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two cases of Graves’ disease following SARS-CoV-2 vaccination[J]. Thyroid, 2021, 31(9): 1436-1439. doi:10.1089/thy.2021.0142pmid:33858208
[15]	Bornemann C, Woyk K, Bouter C. Case report: two cases of subacute thyroiditis following SARS-CoV-2 vaccination[J]. Front Med (Lausanne), 2021, 8: 737142.
[16]	Raashid S, Khan O, Rehman Z, et al. Subacute thyroiditis after receiving inactivated virus vaccine for COVID-19[J]. J Community Hosp Intern Med Perspect, 2022, 12(2):14-17.
[17]	Zettinig G, Krebs M. Two further cases of Graves’ disease following SARS-Cov-2 vaccination[J]. J Endocrinol Invest, 2022, 45(1):227-228. doi:10.1007/s40618-021-01650-0
[18]	Oğuz SH, Şendur SN, Iremli BG, et al. SARS-CoV-2 vaccine-induced thyroiditis: safety of revaccinations and clinical follow-up[J]. J Clin Endocrinol Metab, 2022, 107(5): e1823-e1834. doi:10.1210/clinem/dgac049 URL
[19]	Chattopadhyay S, Chen JY, Chen HW, et al. Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation[J]. Nanotheranostics, 2017, 1(3): 244-260. doi:10.7150/ntno.19796pmid:29071191
[20]	Vartak A, Sucheck SJ. Recent advances in subunit vaccine carriers[J]. Vaccines (Basel), 2016, 4(2): 12.
[21]	Tenforde MW, Self WH, Naioti EA, et al. Sustained effectiveness of pfizer-bioNTech and moderna vaccines against COVID-19 associated hospitalizations among adults[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(34): 1156-1162. doi:10.15585/mmwr.mm7034e2 URL
[22]	Watad A, David P, Brown S, et al. Autoimmune/inflammatory syndrome induced by adjuvants and thyroid autoimmunity[J]. Front Endocrinol (Lausanne), 2017, 7: 150.
[23]	Jara LJ, García-Collinot G, Medina G, et al. Severe manifestations of autoimmune syndrome induced by adjuvants (Shoenfeld’s syndrome)[J]. Immunol Res, 2017, 65(1): 8-16. doi:10.1007/s12026-016-8811-0 URL
[24]	Bragazzi NL, Hejly A, Watad A, et al. ASIA syndrome and endocrine autoimmune disorders[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(1): 101412. doi:10.1016/j.beem.2020.101412 URL
[25]	Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens[J]. Front Immunol, 2021, 11: 617089. doi:10.3389/fimmu.2020.617089 URL

COVID-19 vaccine induced thyroid disease: challenges and strategies

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables1

References25

Related Articles5

Recommended Articles

Metrics

Comments

[1]	Chinese Society of Endocrinology.Guidelines for clinical management of abnormal thyroid function in patients with novel coronavirus infection[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(01): 13-15.
[2]	GU Wei, HOU Liping, LI Xiaolong, GENG Jianlin.Effect of selenium yeast combined with vitamin D on thyroid-associated antibody levels in patients with Hashimoto thyroiditis at different ages[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(06): 392-396.
[3]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(06): 431-434.
[4]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(06): 438-441.
[5]	FU Jiawen, LI Xiaohua, ZHANG Hongli, XU Yanhong, ZHU Yi.Study on the relationship between vitamin D deficiency and Hashimoto’s thyroiditis[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 27-31.